Senza HF10 Therapy
DeviceSenza 10kHz Spinal Cord Stimulation
NCT Number: NCT03228420
This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (Painful Diabetic Neuropathy or PDN). This study is a multi-center, prospective, randomized comparison of the two treatments.
Looking for future studies?
Notify Me22 year and older
All sexes
Interventional
Not applicable
Coastal Orthopedics, Bradenton, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Senza 10kHz Spinal Cord Stimulation
Conventional Medical Management
Time frame: 3 months
Difference between treatment groups in responder rates in subjects without a clinically meaningful neurological deficit compared with baseline. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Time frame: 3 months
Difference between the treatment groups in proportion of subjects with a lower limb pain VAS score ≤ 3 cm.
Time frame: 6 months
Difference between the treatment groups in crossover rates. Subjects who meet pre-specified criteria may elect to crossover to the other treatment arm at 6-month follow-up.
Time frame: 6 months
Difference between the treatment groups in responder rates. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Time frame: 6 months
Difference between the treatment groups in the proportion of remitters (remission is defined as having a lower limb pain VAS score of ≤ 3.0 cm for at least 6 months).
Time frame: 3 months
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Time frame: 6 months
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Time frame: 6 months
Difference between the treatment groups in changes in health-related quality of life as assessed by the EuroQol Five Dimensions questionnaire (EQ-5D-5L).
Time frame: 6 months
Difference between the treatment groups in the average percentage change from baseline in HbA1c levels.
Nevro Corp
Industry
A Post-Market, Multicenter, Prospective, Randomized Clinical Trial Comparing 10 kHz Spinal Cord Stimulation (HF10™ Therapy) Combined With Conventional Medical Management to Conventional Medical Management Alone in the Treatment of Chronic, Intractable, Neuropathic Limb Pain
Acronym: SENZA-PDN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05937984
Diabetes Complications, Diabetes Mellitus
Hamilton, Ontario, Canada
View Trial DetailsNCT05476276
Diabetes Complications, Diabetes Mellitus
San Diego, California, United States
View Trial DetailsNCT05480228
Diabetes Complications, Diabetes Mellitus
San Diego, California, United States
View Trial DetailsNCT06524284
Diabetes Complications, Diabetes Mellitus
Vught, Netherlands
View Trial Details